CUC Valuation
Is 9158 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9158 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 9158 (¥1688) is trading above our estimate of fair value (¥592.41)
Significantly Below Fair Value: 9158 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9158?
Key metric: As 9158 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 9158's PE Ratio? | |
|---|---|
| PE Ratio | 13.9x |
| Earnings | JP¥3.57b |
| Market Cap | JP¥49.48b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.8x |
| Enterprise Value/EBITDA | 9.7x |
| PEG Ratio | 1.5x |
Price to Earnings Ratio vs Peers
How does 9158's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 57.7x | ||
6078 Value HRLtd | 56.1x | n/a | JP¥50.1b |
6099 Elan | 17.2x | 16.4% | JP¥42.3b |
6197 Solasto | 144.2x | 23.5% | JP¥43.6b |
7840 France Bed HoldingsLtd | 13.3x | n/a | JP¥42.7b |
9158 CUC | 13.9x | 9.5% | JP¥49.5b |
Price-To-Earnings vs Peers: 9158 is good value based on its Price-To-Earnings Ratio (13.9x) compared to the peer average (57.7x).
Price to Earnings Ratio vs Industry
How does 9158's PE Ratio compare vs other companies in the JP Healthcare Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 9158 is good value based on its Price-To-Earnings Ratio (13.9x) compared to the JP Healthcare industry average (14.2x).
Price to Earnings Ratio vs Fair Ratio
What is 9158's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 13.9x |
| Fair PE Ratio | 22.6x |
Price-To-Earnings vs Fair Ratio: 9158 is good value based on its Price-To-Earnings Ratio (13.9x) compared to the estimated Fair Price-To-Earnings Ratio (22.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
FINDEX
JP¥20.8b
Offers medical systems, office systems, and Healthtech products in Japan.
3649
JP¥800.00
7D
-0.7%
1Y
-12.5%
Suzuken
JP¥377.2b
Primarily engages in the distribution of pharmaceuticals in Japan and internationally.
9987
JP¥4,946.00
7D
-2.6%
1Y
-1.6%
TOKAI
JP¥75.1b
Provides various healthy life services in Japan.
9729
JP¥2,214.00
7D
0.05%
1Y
16.4%